Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) issued its quarterly earnings data on Thursday. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.15, Analyst Ratings News reports. The company had revenue of $8.30 million for the quarter, compared to the consensus estimate of $10.80 million. During the same quarter in the previous year, the company posted ($0.15) earnings per share. The company’s revenue for the quarter was down 55.4% on a year-over-year basis. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) weekly performance is 0.22%. On last trading day company shares ended up $54.33. Analysts mean target price for the company is $101.00. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) distance from 50-day simple moving average (SMA50) is -14.78%.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) posted its quarterly earnings results on Thursday. The company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.10),Analyst Ratings.Net reports. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares advanced 9.12% in last trading session and ended the day on $3.23. Its return on assets is -108.70%. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) quarterly performance is -19.85%.
Intrexon Corporation (NYSE:XON) a leader in synthetic biology, announced its first quarter results for 2014. Net income attributable to Intrexon of $4.1 million, or $0.04 per common share, for the quarter ended March 31, 2014 compared to net loss attributable to Intrexon of $36.3 million for the quarter ended March 31, 2013; Adjusted EBITDA of $17.6 million, or $0.18 per common share, for the quarter ended March 31, 2014 compared to Adjusted EBITDA of ($7.0) million for the quarter ended March 31, 2013. Intrexon Corp (NYSE:XON) shares moved up 3.01% in last trading session and was closed at $15.76, while trading in range of $13.13 – $15.86 -. Intrexon Corp (NYSE:XON) year to date (YTD) performance is -33.78%.
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) a research and development company with a primary focus in ophthalmology, announced the initiation of a Phase II investigator sponsored clinical trial, OHR-005, testing Squalamine Eye Drops in patients with diabetic macular edema (DME). OHR Pharmaceutical Inc (NASDAQ:OHRP) ended the last trading day at $6.87. Company weekly volatility is calculated as 11.52% and price to cash ratio as 40.53. OHR Pharmaceutical Inc (NASDAQ:OHRP) showed a negative weekly performance of -28.73%.
Leave a Reply